T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis

Archives of Neurology

Volumn 56, Issue 2, 1999, Pages 217-222

  Bongioanni, Paolo ^a   Lombardo, Francesco ^a   Moscato, Gianluca ^a   Mosti, Serena ^a   Meucci, Giuseppe ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; T LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; HUMAN; IMMUNOSTIMULATION; IMMUNOTHERAPY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON-BETA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RECEPTORS, INTERFERON; RECOMBINANT PROTEINS; T-LYMPHOCYTES;

EID: 0033053031     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.2.217     Document Type: Article

References (44)

1. O'Gorman M, Oger J. Cell-mediated immune functions in multiple sclerosis. Pathol Immunopathol Res. 1987;6:241-272.
2. Raine CS. The Dale E. McFarlin memorial lecture: the immunology of the multiple sclerosis lesion. Ann Neurol. 1994;36:S61-S72.
3. Nicola NA. Guidebook to Cytokines and Their Receptors. Oxford, England: Sambrook & Tooze Publication at Oxford University Press: 1994.
4. Ransohoff RM, Benveniste EN. Cytokines and the CNS. London, England: CRC Press Inc. 1996.
5. Trinchieri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today. 1985;6:131-136.
6. Bongioanni P. Immuno-interferon effect on cultured rat astrocytes [abstract]. J Neurol. 1990;237:S49.
7. Perrella O. Carrieri PB, De Mercato R, Buscaino GA. Markers of activated T lymphocytes and T cell receptor gamma/delta+ in patients with multiple sclerosis. Eur Neurol. 1993;33:152-155.
8. Gallo P, Piccinno MG, Pagni S, et al. Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and IFN-γ levels in serum and CSF. J Neurol Sci 1989; 92:9-15.
9. Panitch HS, Haley AS, Hirsch RL, Johnson KP. Exacerbations of MS in patients treated with gamma-IFN. Lancet. 1987;1:893-895.
10. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased production of interferon-γ and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Ann Neurol Scand. 1988;78:318-323.
11. Link J, Soderstrom M, Olsson T, Hojeberg B, Ljungdahl A, Link H. Increased TGF-β, IL-4, and IFN-γ in multiple sclerosis. Ann Neurol. 1994;36:379-386.
12. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I: Clinical results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology. 1993;43:655-661.
13. Durelli L, Bongioanni MR, Cavallo R, et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate. MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 1994;44:406-413.
14. Jacobs L, Cookfair D, Rudick R, et al. and the MS Collaborative Group. Results of a phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis. Ann Neurol. 1994;36:259.
15. IFNB MS Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter, randomized, double blind, placebo-controlled trial. Neurology. 1993;43:662-667.
16. Brod SA, Marshall GD Jr, Henninger EM, Sriram S, Khan M, Wolinsky JS. Interferon-β1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis. Neurology. 1996;46:1633-1638.
17. Novick D, Orchansky P, Revel M, Rubinstein M. The human interferon-γ receptor. Purification, characterization and preparation of antibodies. J Biol Chem. 1987; 262:8483-8487.
18. Fischer T, Thoma B, Scheurich P, Pfizenmaier K. Glycosylation of the human interferon-γ receptor: N-linked carbohydrates contribute to structural heterogeneity and are required for ligand binding. J Biol Chem. 1991;265:1710-1717.
19. 125I-interferon-γ to receptors on human cells. J Biol Chem. 1985;260:1191-1198.
20. 125I-labeled recombinant human γ-interferon to receptors on WISH cells. Proc Natl Acad Sci U S A. 1984;81:5160-5167.
21. Valente G, Ozmen L, Novelli F, et al. Distribution of interferon-γ receptor in human tissues. Eur J Immunol. 1992;22:2403-2412.
22. Faltynek CR, Princler GL. Modulation of interferon-α and interferon-γ receptor expression during T-lymphocyte activation and proliferation. J Interferon Res. 1986;6:639-653.
23. Gibbs VC, Williams SR, Gray PW, et al. The extracellular domain of the human interferon gamma receptor interacts with a species-specific signal transducer. Mol Cell Biol. 1991;11:5860-5866.
24. Fountoulakis M, Lahm HW, Maris A, et al. A 25-kD stretch of the extracellular domain of the human interferon γ receptor is required for full ligand binding capacity. J Biol Chem. 1991;266:14970-14977.
25. Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591-594.
26. Bongioanni P, Lombardo F, Fioretti C, Meucci G. T-lymphocyte immunointerferon receptors in patients with multiple sclerosis. J Neurol. 1996;243:605-610.
27. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
28. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46:907-911.
29. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444-1452.
30. Quality Standards Committee, AAN. Practice advisory on selection of patients with multiple sclerosis for treatment with betaseron. Neurology. 1994;44:1537-1540.
31. Trotter JL, Clifford DB, McInnis JE, et al. Correlation of immunological studies and disease progression in chronic progressive multiple sclerosis. Ann Neurol. 1989;25:172-178.
32. Bertouch JV, Roberts-Thompson PJ, Bradley J. Diurnal variation of lymphocyte subsets identified by monoclonal antibodies. BMJ. 1983;286:1771-1772.
33. McPherson GA. Kinetic, EBDA, Ligand, Lowry. A Collection of Radioligand Binding Analysis Programs. Amsterdam, the Netherlands: Elsevier Science Publishers; 1985;31-102.
34. Noronha AB, Richman DP, Arnason BGW. Detection of in vivo stimulated cerebrospinal fluid lymphocytes by flow cytometry in patients with multiple sclerosis. N Engl J Med. 1980;303:713-717.
35. Hafler DA, Fox DA, Manning ME, et al. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 1985;312:1405-1411.
36. Bongioanni P, Fioretti C, Vanacore R, et al. Lymphocyte subsets in multiple sclerosis: a study with two-color fluorescence analysis. J Neurol Sci. 1996;139:71-77.
37. Faltynek CR, McCandless S, Baglioni C. Single high affinity binding of interferon-γ to receptors on human lymphoblastoid cells: internalization and inactivation of receptors. J Cell Physiol. 1985;123:459-463.
38. Faltynek CR, Princler GL, Ortaldo JR. Expression of IFN-α and IFN-γ receptors on normal human small resting T lymphocytes and large granular lymphocytes. J Immunol. 1986;136:4134-4138.
39. Bama BP, Chou SM, Jacobs B, Yen-Lieberman B, Ransohoff RM. Interferon-β impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol. 1989;23:45-53.
40. Panitch HS, Folus JS, Johnson KP. Beta interferon prevents HLA class II antigen induction by gamma interferon in MS. Neurology. 1989;39(suppl 1): 171.
41. Noronha A, Toscas A, Jensen MA. IFN-beta downregulates IFN-gamma production by activated T cells in MS [abstract]. Neurology. 1991;41(suppl 1): 219.
42. Noronha A, Jensen MA, Toscas A, Sihag S. IFN-beta downregulates tumor necrosis factor release. Neurology. 1992;42(suppl 3):159-160.
43. Rudick RA, Carpenter CS, Cookfair DL, et al. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon-beta. Neurology. 1993; 43:2080-2087.
44. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol. 1990;27:207-210.